Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC).

George R. Blumenschein,Julian R. Molina,Chetan Lathia,T. J. Ong,D. Roth,Prabhu Rajagopalan,Frank V. Fossella,M. S. Kies,Randolph Stuart Marks,A. A. Adjei,Pavur Sundaresan

Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC).

2011

George R. Blumenschein
Julian R. Molina
Chetan Lathia
T. J. Ong
D. Roth
Prabhu Rajagopalan
Frank V. Fossella
M. S. Kies
Randolph Stuart Marks
A. A. Adjei
Pavur Sundaresan

7565 Background: Sorafenib (S) is an oral multikinase inhibtor. The safety, antitumor activity, and pharmacokinetics of the combination of S with B/P/C were evaluated in chemonaive patients (pts) w...

Keywords:

non-small cell lung cancer (NSCLC)
Carboplatin
Bevacizumab
Pathology
Cancer research
Paclitaxel
Sorafenib
Medicine
antitumor activity
dose escalation
Internal medicine
Pharmacokinetics
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations